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In order to ascertain the molecular basis of ATP-mediated drug extrusion by Cdr1p, a multidrug transporter of Candida albicans,
we recently have reported that the Walker A motif of the N-terminal nucleotide biding domain (NBD) of this protein contains an
uncommon cysteine residue (C193; GXXGXGCS/T) which is indispensable for ATP hydrolysis. This residue is exceptionally con-
served in N-terminal NBDs of fungal ABC transporters and hence makes these transporters an evolutionarily divergent group.
However, the presence of a conventional lysine residue at a similar position in the Walker A motif of the C-terminal NBD warrants
the individual contribution of both the NBDs in the ATP-driven efflux function of such transporters. In this study we have inves-
tigated the contribution of this divergent Walker A motif in the context of the full Cdr1p protein under in vivo conditions by swap-
ping these two crucial amino acids (C193K in Walker A motif of N-terminal NBD and K901C in Walker A motif of C-terminal
NBD) between the two NBDs. Both the native and the mutant variants of Cdr1p were integrated at the PDR5 locus as GFP-tagged
fusion proteins and were hyper-expressed. Our study shows that both C193K- and K901C-expressing cells elicit a severe impairment
of Cdr1ps ATPase function. However, both these mutations have distinct phenotypes with respect to other functional parameters
such as substrate efflux and drug resistance profiles. In contrast to C193K, K901C mutant cells were substantially hypersensitive to
the tested drugs (fluconazole, ansiomycin, miconazole and cycloheximide) and were unable to expel rhodamine 6G. Our results for
the first time show that both NBDs influence the Cdr1p function asymmetrically, and that the positioning of the cysteine and lysine
residues within the respective Walker A motifs is functionally not interchangeable.
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Prasad).1. Introduction
Candida albicans is an opportunistic diploid fungus
that causes infections in immunocompromised and
debilitated patients [1–3]. Wide-spread and prolonged
usage of azoles in recent years has led to the rapid
development of the phenomenon of multidrug resist-
ance (MDR) which poses a major hurdle in anti-
fungal therapy. Various mechanisms which contribute
towards the development of multidrug resistance have
been implicated in Candida and some of these include. Published by Elsevier B.V. All rights reserved.
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lanosterol 14a-demethylase [3,4] or overexpression of
drug efflux pumps belonging to the ATP-Binding Cas-
sette (ABC) [5] and Major Facilitator Superfamilies of
transporters (MFS) [6,7]. Among ABC transporters,
Cdr1p has been shown to play a key role in azole resist-
ance in C. albicans as deduced from its high level of
expression found in several azole-resistant clinical iso-
lates recovered from patients receiving long-term anti-
fungal therapy [8,9]. Additionally, a high level of
expression of CDR1 invariably contributes to an in-
creased efflux of fluconazole, thus corroborating its di-
rect involvement in drug efflux [4,10]. Cdr1p thus has
not only acquired significant clinical importance but isFig. 1. (a) Topological model of Cdr1p showing two putative transmembran
TMD comprises six a-helices spanning the lipid membrane. The cytoplasmic
terminus, respectively. (b) Amino acid sequence alignment of NBD1 and NB
bold) the conservation of the cysteine and lysine residues within Walker A. (
substitution carried out in this study.considered a critical factor in design of therapeutic strat-
egies to combat antifungal resistance.
Cdr1p is a 1501 amino acid-long polypeptide, organ-
ized into two homologous halves. Each half is predicted
to include a hydrophilic domain containing a nucleo-
tide-binding domain (NBD), followed by a hydrophobic
transmembrane domain (TMD) comprising six trans-
membrane segments (TMS) (Fig. 1(a)) [11]. The NBDs
of ABC-type transporter proteins are the site of ATP
hydrolysis and hence the hub of energy generation for
drug efflux. Inactivation of these NBDs completely
abrogates the functionality of the pump. Studies on hu-
man MDR1/P-gp, the mammalian homolog of Cdr1p,
suggest that both NBDs are capable of performing ane domains (TMD) and two nucleotide-binding domains (NBD). Each
domains of Cdr1p, i.e. NBD1 and NBD2, are located at the N- and C-
D2 of Cdr1p with other fungal ABC type transporters, highlighting (in
c) Sequence of Walker A motif of Cdr1p, highlighting the amino acid
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the NBDs effectively abolishes hydrolysis at the other
[12]. It is also know that hydrolysis at the two NBDs
may occur in an alternate fashion. However, the ques-
tion whether the two NBDs of Cdr1p are functionally
identical or asymmetrical still remains unanswered.
The amino acid sequence of NBDs contains certain
conserved amino acid stretches, which are critical for this
domains functionality [13]. These include the Walker A
motif with a consensus sequence GxxGxGKS/T where
x represents any amino acid, the Walker B motif with
a hhhhD sequence where h is any aliphatic residue,
and an ABC signature consisting of LSGGQQ/R/KQR.
Structural and biochemical analyses of NBDs show that
the conserved lysine residue within the Walker A motif
binds to the b- and c-phosphates of ribonucleotides
and plays a critical role in ATP hydrolysis [14]. It is
well-established from studies of other ABC transporters
that the mutation of this key lysine residue leads to severe
loss in ATPase activity without significantly affecting
ATP binding [15].
Studies on various ABC transporters have revealed
that ATP hydrolysis and substrate transport are strongly
dependent on cooperativity between NBD1 (N-terminal)
and NBD2 (C-terminal) [16]. Interestingly, though
NBD1 of Cdr1p contains the conservedWalker A (GRP-
GAGCST), the commonly conserved lysine residue with-
in the Walker A motif is replaced by a cysteine which
appears to be a unique feature of most of the fungal
ABC transporters [17]. Conversely, the NBD2 of Cdr1p
contains the commonly conserved lysine (GASGAGKT)
at equivalent position in its Walker A motif. There is a
complete lack of understanding with regard to the func-
tional equivalence of both the NBDs of Cdr1p and the
significance of the variation in their Walker A amino acid
sequence. We have recently cloned and used purified the
soluble domain of NBD1 from the full Cdr1p, to demon-
strate in vitro that the uncommon cysteine 193 present
within the Walker A motif is critical for ATPase activity
[18,19]. Our recent study also has shown that the con-Table 1
List of plasmids and strains used in this study
Name Description
Plasmid
pPS-CDR1GFP Plasmid carrying CDR1-GFP ORF cloned at S
pSJCG-C193K Plasmid pPS-CDR1GFP carrying C193K muta
pSJCG-K901C Plasmid pPS-CDR1GFP carrying K901C muta
pSJCG-C193K/K901C Plasmid pPS-CDR1GFP carrying C193K/K90
Strain
AD1-8u MATa pdr1-3 his1 ura3Dyor1::hisG Dsnq2::his
Dpdr10::hisG Dpdr11::hisG Dycf1::hisGDpdr3:
CDR1GFP AD1-8u cells harboring CDR1GFP ORF inte
SJCG-C193K CDR1GFP cells carrying C193K mutation in C
SJCG-K901C CDR1GFP cells carrying K901C mutation in C
SJCG-C193K/K901C CDR1GFP cells carrying C193K/K901C mutaserved aspartate 327 of Walker B of NBD1 is critical
for ATP binding (unpublished observation).
In the present study we have examined the in vivo sig-
nificance and contributions of the divergent Walker A
motifs of both NBDs of the native Cdr1p with respect
to Cdr1p localization, sensitivity to various drugs,
ATPase activity, and ability to expel substrates from
the cells. Considering all the functional parameters,
our results suggest that NBD1 and NBD2 of Cdr1p
have asymmetric contributions to the Cdr1p function.2. Materials and methods
2.1. Strains and media
Plasmids were maintained in Escherichia coli DH5a.
E. coli was cultured in Luria-Bertani medium (Difco),
to which ampicillin was added (100 lg ml1) as required.
The bacterial and Saccharomyces cerevisiae strains used
in this study are listed in Table 1. The yeast strains were
cultured in YEPD broth (1% yeast extract, 2% peptone
and 2% glucose (HiMedia, Mumbai, India), or in SD
ura drop-out media (0.67% YNB, 0.2% drop-out mix
and 2% glucose, Difco). For agar plates, 2% (w/v)
Bactoagar (HiMedia) was added to the medium. All
chemicals used in this study were of analytical grade.
2.2. Site-directed mutagenesis of CDR1 and generation of
transformants
Site-directed mutagenesis was performed by using the
QuikChange mutagenesis system from Stratagene (La
Jolla, CA, USA). The mutations were introduced into
plasmid pPSCDR1-GFP according to the manufac-
turers instructions. The primers used for this purpose
were complementary oligonucleotides harboring C193K
and K901C mutations (Table 2). The desired alterations
in nucleotide sequence were confirmed by DNA sequenc-
ing of the ORF. The mutated plasmid pPSCDR1-GFP,Reference
peI site of pSKPDR5PPUS [21]
tion in CDR1 ORF This study
tion in CDR1 ORF This study
1C mutation in CDR1 ORF This study
G Dpdr5::hisG
:hisG Dpdr15::hisG
[23]
grated at PDR5 locus This study
DR1 ORF and integrated at PDR5 locus This study
DR1 ORF and integrated at PDR5 locus This study
tion in CDR1 ORF and integrated at PDR5 locus This study
Table 2
List of oligonucleotides used in this study
Sequence Purpose
C193K/F 5 0-GGGAGACCCGGTGCTGGTAAATCCACATTGTTAAAGACC-3 0 Forward primer for mutating C! K
at 193 amino acid position
C193K/R 5 0-GGTCTTTAACAATGTGGATTTACCAGCACCGGGTCTCCC-3 0 Reverse primer for mutating C! K
at 193 amino acid position
K901C/F 5 0-CATTGTTGAATTGTTTATCTGTGTGAGTCACTACTGGTATTATTA-3 0 Forward primer for mutating K! C
at 901 amino acid position
K901C/R 5 0-TAATAATACCAGTAGTGACTCACACAGATAAACAATTCAACAATG-30 Reverse primer for mutating K!C
at 901 amino acid position
NBD1F 5 0-CGGGGATCCTCAGATTCTAAGATGTCG-3 0 For sequencing
NBD1R 5 0-CGCGGATCCCGACGGATCACCTTTCAT-3 0 For sequencing
NBD1F-DWA 5 0-CGGGATCCAAGACCATTGCTGTTAAC-30 For sequencing
NBD1R-DWB 5 0-CGGAATTCTCTTTCACCACCGGAAAC-30 For sequencing
CDF10 5 0-CATTACCGTGGTAAAGTTATTTATTCTGC-3 0 For sequencing
CDR10 5 0-GCAGAATAAATAACTTTACCACGGTAATG-30 For sequencing
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8u cells for uracil prototrophy by a lithium acetate-
based method of transformation [20]. Genomic DNA
was isolated from the transformants thus obtained using
a previously described procedure [21,22]. Genomic DNA
was digested with restriction endonuclease (EcoRV,
BamHI, and PstI; Roche Biochemicals). Digested geno-
mic DNA (10 lg) was separated on a 1%-agarose gel
and transferred to a Hybond+ nylon membrane (Amer-
sham). Membranes were hybridized with a a-32P-labeled
dATPCDR1-specific probe (ORF nucleotides 1–280) un-
der high-stringency conditions [7].
2.3. Preparation of plasma membrane proteins
Purified plasma membrane (PM) fractions of yeast
cells were prepared as described previously [23,24]. The
PM protein concentration was determined by Bradford
assay using bovine serum albumin as the standard.
2.4. Immunodetection of Cdr1p and its mutants
Protein samples (10 lg) were separated by eletropho-
resis on sodium dodecyl sulfate-polyacrylamide (SDS)
gels (8% acrylamide) and either stained with Coomassie
blue or electroblotted onto nitrocellulose membrane
(Highbond-C; Amersham). For Western blots, mem-
branes were incubated with a 1:5000 dilution of anti-
GFP antibody (BD Biosciences Clontech, Palo Alto,
CA, USA), or 1:100 dilution of anti-Pma1p (plasma
membrane ATPase) antibody. Immunoreactivity was
detected using horseradish peroxidase-labeled antibody
with a dilution of 1:5000 using the enhanced chemilumi-
nescence assay system (ECL kit, Amersham).
2.5. Drug susceptibility assay
Drug susceptibilities of yeast strains were measured by
three independent methods: filter disk assay, spot assayand minimum inhibitory concentration, as described ear-
lier [25].
2.6. ATPase assay
The amount of inorganic phosphate (Pi) released
from the PM fraction of cells expressing either native
or mutant variant of Cdr1p was measured as described
previously [18,23,26].
2.7. Rhodamine 6G efflux assay
The efflux of rhodamine 6G (R6G) from S. cerevisiae
cells was determined as previously reported [26]. The
R6G fluorescence of the samples was measured with
a Cary Eclipse spectrofluorimeter (Varian, Inc.,
Australia).3. Results
3.1. Mutations in the Walker A motifs of NBD1 and
NBD2 do not affect Cdr1p localization and expression
The significance of the presence of uncommon cys-
teine and invariant lysine in Walker A of NBD1 and
NBD2, respectively, was examined by mutating Cys
193 to Lys (C193K) and Lys 901 to Cys (K901C)
(Fig. 1). For this we used a hyper-expression system
where Cdr1p was stably overexpressed from the PDR5
locus in a S. cerevisiae mutant, AD1-8u. The AD1-
8u was derived from a Pdr1-3 mutant strain with a
gain-of-function mutation in the transcription factor
Pdr1p, resulting in a constitutive hyperinduction of the
PDR5 promoter [23,26]. The cells expressing these mu-
tant variants of NBDs were designated as SJCG-
C193K, SJCG-K901C and SJCG-C193K/K901C (Table
1). The stable single-copy integration in our heterolo-
gous hyper-expression system was confirmed by Southern
Fig. 2. (a) Confocal images of Saccharomyces cerevisiae cells expressing GFP-tagged Cdr1p and its mutant variants. Cells were washed and
resuspended in an appropriate volume of 50 mM HEPES, pH 7.0, and placed on the glass slides; a drop of antifade reagent (Fluoroguard high
performance antifade reagent, Biorad, Hercules, CA) was added to prevent photobleaching. The cells were directly viewed with 100· oil immersion
objective on a Biorad confocal microscope (MRC 1024). (b) Expression profile of wild-type and mutant Cdr1 proteins. PM of wild- type and mutant
proteins were prepared as described earlier [24]. Immunodetection of the proteins was performed by running the samples (as indicated) on a 8% SDS–
PAGE and transferring to nitrocellulose membrane (electrophoretically), followed by probing with anti-GFP antibody and anti-Pma1 antibody and
detecting by chemiluminescence using an ECL Kit (Amersham).
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of native Cdr1p was confirmed by confocal microcopy.
The well-defined green-rimmed appearance in confocal
images clearly confirmed that the GFP-tagged Cdr1p
and its mutant variants were properly localized to the
plasma membrane (PM) (Fig. 2(a)). The localization of
Cdr1p in the hyper-expression system was further veri-
fied by probing with plasma membrane-specific anti-
body (Pma1). For this, equal amounts of purified PM
proteins isolated from SJCG-C193K, SJCG-K901C
and SJCG-C193K/K901C cells were loaded and sepa-
rated on 8% SDS–PAGE and the proteins were trans-
ferred to nitrocellulose membrane (Amersham). The
resolved proteins were probed with anti-GFP antibody.
The results are depicted in Fig. 2(b), where it is evident
that the expression levels of Cdr1p variants in PM of
mutants and wild type were similar. Stripping and
reprobing of the same blot with anti-Pma1 antibody
(kind gift from R. Serrano, Valencia) validated the puri-
fied PM preparations (Fig. 2(b), lower panel). The con-
focal data and Western blotting excluded the possibility
of mislocalization and altered expression of Cdr1p due
to mutation within Walker A of NBD1 and NBD2.3.2. Mutations in NBD1 and NBD2 differentially affect
the drug susceptibility of C. albicans
We examined the effect of mutations in Walker A of
Cdr1p on drug sensitivity of cells expressing mutantproteins by three independent drug susceptibility assays:
filter disc, spot assay, and MIC.
As can be judged from the size of inhibition zones in
filter disc assays (Fig. 3) the host cells (AD1-8u) were
expectedly sensitive to all the tested drugs, i.e. fluconaz-
ole (FLC), miconazole (MIC), cycloheximide (CYH)
and ansiomycin (ANS). In contrast, the transformants
harboring Cdr1p (CDR1-GFP) wild-type protein
showed a high degree of resistance, evident from the
zone of inhibition which was either reduced (ANS and
MIC) or completely absent (FLC and CYH) at the indi-
cated concentrations (Fig. 3). Compared to the wild-
type cells (CDR1-GFP), the C193K mutants showed a
modest increase in sensitivity to FLC and ANS, and a
650% rise in sensitivity to MIC and CYH. Interestingly,
the cells expressing the Walker A mutant (K901C) of
NBD2 were hypersensitive to all the tested drugs, and
their level of drug susceptibility was comparable to that
of host cells (AD1-8u). The simultaneous mutations in
both NBDs (C193K/K901C) resulted in hypersensitivity
to all the tested drugs, to the level comparable to that of
host cells (AD1-8u).
In order to further validate the above-mentioned
observation, drug susceptibilities of native and mutant
protein-expressing cells was examined by employing
two other independent methods, i.e. spot and MIC as-
says. In spot assays, the host strain (AD1-8u) was
expectedly sensitive to all the drugs when compared to
the growth control (without drug). Conversely, substan-
tial growth in presence of drugs was observed for the
Fig. 3. Drug resistance profiles of wild-type and Walker A mutants determined by filter disc assay as described earlier [25]. For filter disc assay, the
drugs were spotted in a volume of 1 to 5 ll at the indicated amounts: fluconazole (64 lg ml1), anisomycin (32 lg ml1), miconazole (0.25 lg ml1)
and cycloheximide (0.25 lg ml1). Cells were incubated at 30 C for 48 h and the zone of inhibition for each drug was measured.
Fig. 4. Drug resistance profiles of wild-type and Walker A mutants determined by spot assays and minimum inhibitory concentration as described
earlier [25]. In the spot assay, 5 ll of five-fold serial dilutions of each yeast culture (each with cells suspended in normal saline to an OD of 0.1 (A600))
were spotted on YEPD plates in absence (control) and presence of the following drugs: fluconazole (1 lg ml1), anisomycin (6 lg ml1), miconazole
(0.1 lg ml1) and cycloheximide (0.15 lg ml1).
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1 lg ml1 of FLC, 6 lg ml1 of ANS, 0.1 lg ml1 of
MIC and 0.15 lg ml1 of CYH, mutant variant
C193K- and K901C-expressing cells showed substantial
differences in sensitivity to these drugs. It is evident from
Fig. 4 that, while mutant C193K continued to grow at
these concentrations of most of the drugs (except MIC
where C193K cells did not show any growth), the cells
expressing K901C or C193K/K901C showed almost no
growth with these drugs, thus displaying hypersensitivity
(Fig. 4). The results of the microdilution method also
corroborated the drug sensitivity profile of cells express-
ing native or mutant Cdr1p. Interestingly, there was adifference in minimum inhibitory concentrations
between C193K and K901C which indicated the asym-
metric affect of these mutations (Table 3). The results
of all three independent drug sensitivity tests established
that the two mutations in Walker A motifs of NBD1
and NBD2 have differential effect on Cdr1p-mediated
drug resistance.
3.3. ATPase activity is affected by NBD mutations
We performed ATPase assays with the PM of wild
type and mutants to ask the question whether mutations
in NBDs in any way affect the ATPase activity of the full
Table 3
Drug resistance profiles of wild-type Cdr1p and its NBD mutants
Minimum inhibitory concentration (lg ml1)a
Fluconazole Anisomycin Miconazole Cycloheximide
AD1-8u 0.25 0.12 0.3 0.007
SJCDR1GFP 64 32 2 1
SJCG-C193K 8 8 0.5 0.125
SJCG-K901C 1 2 0.25 0.016
SJCG-C193K/K901C 0.5 0.25 0.3 0.007
a Determined following National Committee for Clinical Laboratory Standards.
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drug susceptibility phenotypes. The purified PM frac-
tion from cells expressing native Cdr1p (CDR1-GFP)
exhibited a significant increase in the ATPase activityFig. 5. (a) Comparison of ATPase activity of Cdr1p with its mutants. ATPas
K901C and C193K/K901C) was assayed and each reaction was performed in
independent experiments. (b) Comparison of R6G efflux between wild-type an
[26] and incubated with R6G at 30 C for 2 h. Glucose (2%) was added and at
concentration of R6G in the supernatant was determined spectrofluorometr
concentration of R6G in the supernatant 30 min after the addition of glucose
means (indicated by the bars) ± standard deviations of three independent exas compared to that of the host cells (AD1-8u). This
substantial and hence measurable difference in oligomy-
cin-sensitive ATPase activity gave us an opportunity to
look for the effect of mutations in the divergent Walkere activity of the wild type (Cdr1p) and the Walker A mutants (C193K,
triplicate; the values plotted (with ±SD) represent the average of three
d Walker A mutant cells. Cells were de-energized as detailed elsewhere
different time points cells were rapidly centrifuged and the extracellular
ically [26]. R6G efflux is represented by bars showing the extracellular
to the cells in wild-type and Walker A mutant cells. The values are the
periments.
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observed a clear and distinct difference between ATPase
activity of the PM prepared from the wild type and from
mutants. Substitution of Cys 193 to Lys (C193K) in
Walker A motif of NBD1 resulted in a 78% decrease
in its ability to hydrolyze ATP, while Lys 901 to Cys
(K901C) had a more severe effect as it had only 12%
of the native protein activity. The simultaneous substitu-
tion of Cys 193 and Lys 901 (C193K/K901C) reduced
the ATPase activity to 610% of that of the native pro-
tein (Fig. 5(a)). The results of ATPase assays suggested
that there is a differential effect, albeit not very large, on
the ability to hydrolyze ATP when Cys 193 or Lys 901
are substituted independently (C193K, K901C) or
simultaneously (C193K/K901C).
3.4. R6G efflux suggests asymmetry in substrate export
ability between NBD1 and NBD2
The difference in the ability to hydrolyze ATP and the
sensitivity to drugs further lead us to the question
whether there is an asymmetry between NBD1 and
NBD2 of Cdr1p with regard to their ability to expel sub-
strates. We monitored rhodamine 6G (R6G) efflux in
energy-depleted cells expressing native or mutant vari-
ant Cdr1p. The ability of Cdr1p to expel R6G from
the cells is ATP-dependent, as has been established ear-
lier by us as well as by others [26]. In this study, when
R6G efflux was carried out with cells expressing the var-
iant Walker A mutants of Cdr1p and compared with
that of cells expressing the native protein, we observed
K901C and K901C/C193K double substitution to signif-
icantly affect the R6G efflux ability of Cdr1p, correlated
well with the observed hypersensitivity to tested drugs
displayed by these mutants. However, drug-sensitive
C193K mutant cells showed efflux levels of R6G compa-
rable to those of native-protein-expressing cells (Fig.
5(b)). Thus the substitution of conserved Lys 901 of
NBD2 and atypical Cys 193 resulted in an asymmetrical
effect on their expulsion ability.4. Discussion
Multidrug resistance has been linked with ABC trans-
porters in many disease-causing organisms, including
several fungal pathogens, and human cancers [1–3].
Although we have a fair understanding of drug-binding
and catalytic function of mammalian ABC drug trans-
porters such as human P-gp/MDR1 and MRPs, the
same is unfortunately not true for fungal transporters.
Considering the importance of ABC transporters like
Cdr1p and Cdr2p in azole resistance commonly encoun-
tered in clinical isolates of C. albicans, we have been
functionally characterizing Cdr1p [18,19,23]. Recently,
by using a soluble purified N-terminal NBD1 domainof Cdr1p, we have demonstrated that this domain elicits
a cation dependent general ribonucleotide triphospha-
tase activity [18]. We also have found an evolutionary
divergence in this domain wherein a conserved variation
exists within the catalytically crucial Walker A motif of
NBD1 [18]. Reports from other systems suggest that the
Walker A motifs of NBDs and especially the well-con-
served lysine residue within it are indispensable for
ATP hydrolysis, hence its mutation to Arg or Met in
either or both NBDs abrogates the drug transport and
ATPase activities of mammalian ABC transporters
[15]. Our study has highlighted the evolutionary devia-
tion and conservation of cysteine (GxxGxGKS/T) resi-
due instead of a typically found lysine in the Walker A
motif of NBD1 of Cdr1p and other fungal transporters.
By both biochemical analyses and deduced structural
homology modeling, we have demonstrated the indis-
pensability of this evolutionarily divergent Cys 193 in
ATP hydrolysis [18,19]. However, since these observa-
tions were an outcome of analyses of an in vitro isolated
domain, we wanted to understand the significance of
variant Walker A motifs of NBD1 and NBD2 in the
context of the full protein. The present in vivo study
was designed to explore the relative contribution of both
the N- and C-terminal NBDs in ATP-binding, hydroly-
sis and transporter activity of Cdr1p. In order to address
these questions, we swapped atypical Cys 193 of Walker
A of NBD1 (C193K) and conserved Lys 901 (K901C) of
Walker A of NBD2. The effect on ATP hydrolysis and
transport activity of such substitution in the full protein
of Cdr1p or of its mutant variants was studied using a
heterologous hyper-expression system [23]. We observed
that mutation within the Walker A of both the NBDs
did not affect the expression and the localization of the
mutant variant protein, as was evident from Western
blots and GFP-tagged fluorescence (Fig. 2). Of note,
we earlier had observed that mutant variant C193K in
Walker A of the NBD1 domain where Cys 193 was re-
placed by Lys resulted in an unstable protein ([18] and
unpublished data). Interestingly, C193K mutation in
the whole protein (this study) did not affect its stability.
The drug resistance profile of Cdr1p C193K or
K901C mutants gave an interesting insight into the func-
tioning of the two NBDs. Indeed, cells expressing both
mutant variants were sensitive to all the tested drugs
but there was a drastic difference in their level of
sensitivity, as was revealed by three independent drug
susceptibility assays. The cells expressing K901C were
hyper-sensitive to drugs when compared to the C193K
variant or to native Cdr1p. This clearly established that
the two NBDs respond asymmetrically to the substitu-
tion of conserved residues of their respective Walker A
motifs. The divergence in functioning of the two NBDs
was further evident when we compared the export abil-
ity of these mutant proteins. It was observed that the ex-
port of the fluorescent substrate R6G by a Cdr1p was
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pared to cells expressing the C193K variant. It is intrigu-
ing why substitution of C193 does not result in
significant impairment of R6G efflux as compared to
the K901 mutation. An in-depth analysis of the catalytic
cycle, i.e. nucleotide binding, hydrolysis and substrate
binding/efflux will be required to answer the questions
behind the dichotomy in functioning of the NBDs. This
study, however, demonstrates that a diverse N-terminal
NBD (GxxGxGCS/T) of Cdr1p is functional where
uncommon C193 is critical. Considering that all other
fungal ABC transporters, including the well-studied
Pdr5p of S. cerevisiae, have the uncommon cysteine in
Walker A of NBD1 (with the exception of Ste6p of
S. cerevisiae), it is expected that this residue will have
an indispensable role in the catalytic cycle [17].
The purified PM isolated from cells expressing mu-
tant variants of Cdr1p showed that replacements of
C193K and K901C in Walker A of NBD1 and NBD2
resulted in 78% and 88% impairment of ATPase activity,
respectively (Fig. 5). It would mean that the swapping of
the cysteine and lysine residues in the Walker A between
the two NBDs could not retain the normal ATPase
function of the native protein. This further not only sig-
nifies the crucial positioning of the C193 and K901 at
their respective domains, but also demonstrates that
the swapping of the two residues within the two NBDs
is intolerable to the Cdr1p function. The difference in
loss of ATPase activity between the two mutant proteins
was not substantial; therefore, the activity cannot be di-
rectly correlated with the differences observed between
C193K and K901C mutant proteins with regard to drug
resistance and efflux of R6G. Since both mutations
occurring independently and simultaneously impaired
ATPase function substantially, it is difficult to comment
if there are any synergestic contributions of these muta-
tions. Based on overall results, it is clear that the two
NBDs of Cdr1p function divergently in vivo. Of note,
the C193A mutation and K901A in the full protein also
showed impaired ATPase activity (data not shown).
The two NBDs of a number of ABC transporters have
been shown to be functionally divergent, playing different
roles in the transport process. In prokaryotic ABC type
transporters such as the histidine permease ofE. coli, both
NBDs are functionally identical and equally contributive
to the proteins activity. Inactivation of either one of these
NBDs in the full protein results in a transporter that has
its activities reduced to 50%. On the other hand, the
NBDs of the eukaryotic transporters such as the human
P-gp/MDR1, CFTR (Cystic Fibrosis Transmembrane
conductance Regulator) and MRP1, though highly con-
served and similar in sequence, do not appear to be func-
tionally complementary, as inactivation of either of them
completely abolishes ATPase and transport activities of
the protein [15]. The whole issue whether the two NBDs
are functionally identical or asymmetric remains to beresolved. In this context our present study clearly demon-
strates that the multidrug ABC transporter Cdr1p of
pathogenic C. albicans possesses functionally divergent
NBDs. These results would pave ways to understand
the catalytic cycle of drug efflux involving the two NBDs
of this medically important ABC drug transporter.Acknowledgements
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